Public Reporting of Hospital Readmissions Hasn't Cut Rates

Share this content:
Public Reporting of Hospital Readmissions Hasn't Cut Rates
Public Reporting of Hospital Readmissions Hasn't Cut Rates

THURSDAY, Feb. 25, 2016 (HealthDay News) -- For patients with myocardial infarction (MI), heart failure, and pneumonia, the release of the Centers for Medicare & Medicaid Services (CMS) public reporting of hospital readmission rates has had no impact on 30-day readmission trends, according to a study published in the March 1 issue of the Journal of the American College of Cardiology.

Adam D. DeVore, M.D., from the Duke Clinical Research Institute in Durham, N.C., and colleagues analyzed Medicare claims data from 2006 to 2012 for patients discharged after hospitalization for MI, heart failure, or pneumonia.

Data were included from >4,100 hospitals for 37,829 hospitalizations for MI, 100,189 for heart failure, and 79,076 for pneumonia. The researchers found that there were improvements in adjusted readmission rates for MI (−2.3 percent), heart failure (−1.8 percent), and pneumonia (−2.0 percent) when considering only recent trends (since 2009). When comparing trends before with those after reporting, there was no difference for MI, heart failure, or pneumonia (P = 0.72, 0.19, and 0.21, respectively). No changes were seen in 30-day post-discharge care for MI or pneumonia; for heart failure there were deceases in emergency department visits and for observation stays (P = 0.007 and 0.04, respectively).

"In this analysis of Medicare claims data, we found no association between the 2009 CMS policy decision to report hospital readmission rates and changes in trends for readmission rates publicly," the authors write.

Several authors disclose financial ties to the biopharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »